clinicalstage

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

September 02, 2025 21:33 ET  | Source: Mineralys Therapeutics, Inc. RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics,…

1 day ago

Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

WALTHAM, Mass., Sept. 01, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory…

2 days ago

Vaxart Granted Extension by Nasdaq to Regain Compliance

August 29, 2025 08:00 ET  | Source: Vaxart, Inc. - Company must regain compliance with the Nasdaq Bid Price Rule…

6 days ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

BOSTON, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights…

6 days ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

BOSTON, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing…

1 week ago

Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC:…

2 weeks ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Celebrates Indian Independence Day by Honoring the US-India Innovation PartnershipCAMBRIDGE, Mass.--(BUSINESS WIRE)--$HIND--Vyome Holdings (Nasdaq: HIND), a clinical-stage healthcare holding company…

3 weeks ago

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…

3 weeks ago

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 01, 2025 17:06 ET  | Source: Taysha Gene Therapies, Inc. DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene…

1 month ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

July 25, 2025 16:15 ET  | Source: Portage Biotech Inc. DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech…

1 month ago